Mechanism of Action
12.1 Mechanism of Action ARIKAYCE is an antibacterial drug [see ]. 12.2 Pharmacodynamics ARIKAYCE exposure-response relationships and the time course of pharmacodynamic response are unknown. 12.3 Pharmacokinetics Sputum Concentrations Following once daily inhalation of 590 mg ARIKAYCE in…
Aminoglycoside Antibacterial
Clinical Trials (5)
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria